Advertisement

Topics

GSK confirms departure of R&D chief

05:39 EST 9 Nov 2017 | PharmaTimes

Ending days of speculation GlaxoSmithKline has now confirmed the departure of its current R&D chief Patrick Vallance. The drugs giant has also presented new data for lupus drug Benlysta.

Original Article: GSK confirms departure of R&D chief

NEXT ARTICLE

More From BioPortfolio on "GSK confirms departure of R&D chief"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

GlaxoSmithKline
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...